Vitestro Raises $70 Million to Advance Autonomous Blood Collection Robot

Dutch medical robotics company Vitestro has raised $70 million in an oversubscribed Series B round to advance its autonomous robotic blood collection system, announced in a press release. The funding includes new strategic investments from Labcorp Venture Fund, Mayo Clinic, and Sutter Health, alongside financial investors such as InterVest, MGFO, PGGM, Puma Venture Capital, and ROM Utrecht.

The proceeds will be used to further develop the next-generation Aletta Autonomous Robotic Phlebotomy Device (ARPD), expand clinical and manufacturing operations, and prepare for global commercialization. Vitestro also plans to pursue U.S. FDA De Novo regulatory clearance as it progresses from European market entry toward the U.S.

Aletta uses multimodal imaging, robotics, and artificial intelligence to identify veins, guide needle insertion, and collect samples autonomously. The device is designed to standardize blood collection quality, support clinical workflows, and reduce staffing pressures in high-volume outpatient settings.